Associations of chronic hepatitis C with metabolic and cardiac outcomes

Younossi, Zobair M.; Stepanova, Maria; Nader, Fatema; Elsheikh, Elzafir

doi:10.1111/apt.12234

Cited by 144 publications

(142 citation statements)

References 31 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…15,16,37 The relative impact of the observed increase in LDL concentration associated with HCV clearance, shown here and in other studies, with the decrease observed in other biomarkers of cardiovascular disease observed with HCV clearance on subsequent risk for cardiovascular events requires prospective evaluation. 38 We also demonstrate that an LDL increase occurs with slower kinetics than the decline in HCV viral load in serum during treatment (Fig.…”

Section: Discussionmentioning

confidence: 73%

“…15,16 HCV modulation of serum cholesterol is in part related to viral intrahepatic modulation of cholesterol biosynthesis, and HCV circulates with host lipoproteins in complexes termed lipoviral particles. 14,[17][18][19][20][21][22] While HCV genotype-3 (GT3) is notable for inducing hepatic steatosis and having the most marked reduction of serum lowdensity lipoprotein (LDL) among the HCV genotypes, infection with HCV GT1, the most common genotype in the United States, is also associated with insulin resistance and altered LDL concentrations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Townsend

Meissner

Sidharthan

et al. 2016

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is associated with lower serum concentration of low-density lipoprotein (LDL-C), the primary cholesterol metabolite targeted pharmaceutically to modulate cardiovascular risk. Chronic infection with human immunodeficiency virus (HIV) and treatment with antiretrovirals (ARVs) are associated with dyslipidemia and increased risk of cardiovascular disease. In subjects coinfected with HIV and HCV, lipid abnormalities associated with either infection alone are often attenuated. Treatment of chronic HCV infection in HIV/HCV-coinfected subjects is now possible with interferon (IFN)-free regimens composed of directly acting antivirals (DAAs). We previously observed a marked increase in serum LDL-C in HCVmonoinfected subjects treated with sofosbuvir and ribavirin (SOF/RBV) that correlated with viral decline in serum, suggesting a direct influence of HCV clearance on serum cholesterol. In the present study, we assessed longitudinal changes in cholesterol in HIV/HCV-coinfected subjects during treatment of HCV genotype-1 (GT1) infection with combination DAA therapy. We report a rapid increase in LDL-C and LDL particle size by week 2 of treatment that was sustained during and after treatment in HIV/HCV-coinfected subjects. No change in serum LDL-C was observed at day 3 of treatment, in spite of a marked reduction in serum HCV viral load, suggesting LDL-C increases do not directly reflect HCV clearance as measured in peripheral blood. After effective DAA therapy for HCV, an increase in LDL should be anticipated in HIV/HCV-coinfected subjects.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Townsend

Meissner

Sidharthan

et al. 2016

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…[4][5][6] Furthermore, it is involved in the development of insulin resistance and accelerates fibrosis progression, as well as can lead to advanced liver disease and hepatocellular carcinoma and raises mortality. 4,[7][8][9] Historically, peginterferon-alpha plus ribavirin has been the established treatment for GT-3 patients, which has led to sustained virologic responses in 70% to 80% of patients. 4,[10][11][12][13] Fibrosis or cirrhosis were predictive of reduced sustained virologic response; therefore, GT-3 patients with cirrhosis were especially hard to treat.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Teegen

Globke²,

Schott³

et al. 2018

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Historically, hepatitis C virus genotype 3 infection has not been as hard to treat as genotype 1 using interferon-based therapy. Now, genotype 3 infection can be treated using interferon-free regimes such as the combination of sofosbuvir and daclatasvir, which is a highly successful and reliable therapeutic option before liver transplant. However, real world data are rather limited regarding the use of antivirals (sofosbuvir/daclatasvir) for hepatitis C virus genotype 3 recurrence after liver transplant. Here, we present the results of antiviral treatment with sofosbuvir and daclatasvir in patients with genotype 3 recurrence after liver transplant and also viewed published data, to finally close the chapter on genotype 3 elimination. Materials and Methods: We analyzed 11 patients who received liver transplants due to hepatitis C virus genotype 3-associated cirrhosis at our center. Two patients were naïve for any antiviral therapy. All patients received antiviral treatment with sofosbuvir/daclatasvir for 12 weeks after liver transplant, with 1 patient also having ribavirin. The endpoint was hepatitis C virus RNA-free survival after 12 weeks of therapy. Secondary endpoints were preservation of renal and liver function and incidence of adverse events. Results: All patients were free of hepatitis C virus RNA by at least 8 weeks after therapy initiation. Elevated transaminases and gamma-glutamyltransferase at the beginning of therapy normalized quickly during treatment. Synthesis and excretion were stable at all dates. Patients displayed no severe adverse effects, especially regarding renal function and blood counts. Sustained virologic response rates at week 12 were achieved in all 11 patients. Conclusions: Hepatitis C virus could be eliminated in all patients after liver transplant with 12-week sofosbuvir/daclatasvir therapy. Sofosbuvir combined with daclatasvir is safe and reliable for recurrent hepatitis C virus genotype 3 infection. Our results have closed the chapter on genotype 3 recurrence after liver transplant in our outpatient clinic.

show abstract

“…4%) in patients with HCV infection than in those with other forms of chronic hepatitis. [12][13][14][15] CLD and type 2 diabetes mellitus are two chronic conditions which contribute to a significant morbidity and mortality. Literature is scarce regarding the occurrence of type 2 diabetes mellitus in CLD in Bangladesh.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Type 2 Diabetes Mellitus in patients with Chronic Liver Disease

et al. 2017

View full text Add to dashboard Cite

(T2DM) is caused by a combination of genetic factors and lifestyle factors like obesity, lack of physical activity and stress. T2DM can develop in chronic liver disease (CLD) though its actual mechanism is not fully understood. In case of hepatitis B virus (HBV) related CLD, HBV infection has been directly related to development of abnormal glucose metabolism by pancreatic islets cell injury. Development of Insulin resistance in case of hepatitis C virus (HCV) is the key pathogenesis of development of type 2 diabetes. We aimed to study the magnitude of the problem of T2DM among the patients with various types of CLD and to find out the association of diabetes mellitus with the demographic and clinical characteristics of the patient admitted in Medicine ward in Dhaka Medical College Hospital.

show abstract

Associations of chronic hepatitis C with metabolic and cardiac outcomes

Abstract: SUMMARY BackgroundChronic hepatitis C virus (CH-C) infection is associated with metabolic conditions such as insulin resistance and type 2 diabetes (DM) and may increase the risk of cardiovascular diseases.

Cited by 144 publications

References 31 publications

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration

Untitled

Prevalence of Type 2 Diabetes Mellitus in patients with Chronic Liver Disease

Contact Info

Product

Resources

About